Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Cancer Discov. 2011 Jun 17;1(3):248–259. doi: 10.1158/2159-8290.CD-11-0085

Figure 1. AZD8055 is a potent inhibitor of mTORC1 and mTORC2 signaling.

Figure 1

(A) Immunoblot analysis was performed on mTORC1 and mTORC2 effectors after treatment with increasing concentrations of AZD8055 or rapamycin for four hours in MCF-7, BT-474 and MDA-MB-468 breast cancer cells. (B) The same cell lines were treated with 500nM of AZD8055 and collected at indicated times and analyzed by immunoblotting.

HHS Vulnerability Disclosure